News und Analysen

If you're an everyday investor looking for stocks that can deliver steadily rising dividend payouts over long periods, the healthcare sector is the right place to begin your search. People get sick

One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1)

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

2024 is off to a great start for many investors, with the S&P 500 climbing 10.2% in the first quarter, roughly the performance the index averages for an entire year. Since the end of 2022, the S&P

Medical Properties Trust (NYSE: MPW) has fallen on hard times over the past few years. Shares of the hospital-focused real estate investment trust (REIT) have lost more than 80% of their value from

Medical Properties Trust (NYSE: MPW) has fallen on hard times over the past few years. Shares of the hospital-focused real estate investment trust (REIT) have lost more than 80% of their value from

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor

Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have an approved drug fighting for market share

Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.

That's what has happened this year to Viking Therapeutics (NASDAQ:

Investors are very eager to buy into biotechs and pharmaceuticals that are involved in developing weight-loss medications. This is why Viking Therapeutics (NASDAQ: VKTX), which has such a drug in

Shares of Novocure (NASDAQ: NVCR) were jumping 6.3% higher as of 11:15 a.m. ET on Thursday after rising as much as 9.2% earlier in the day. The nice gain came after the company announced results

Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because

What's the hottest biotech stock on the market right now? If we limit the list only to those with market caps of at least $500 million, it's Viking Therapeutics (NASDAQ: VKTX). So far in 2024

Shares of Medical Properties Trust (NYSE: MPW) soared 18.6% on Wednesday after the largest tenant of the healthcare facilities-focused real estate investment trust (REIT) announced a deal to sell

Shares of Medical Properties Trust (NYSE: MPW) soared 18.6% on Wednesday after the largest tenant of the healthcare facilities-focused real estate investment trust (REIT) announced a deal to sell

Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an

When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but

Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those